InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.105 -0.18 (-63.16%)+
Announcement
Release
11 Feb 2026 8:17AM
Price at Release
$0.285
Full Release
download
Summary
Argenica Therapeutics Limited reported a significant financial loss of $3,816,831 for the half-year ended 31 December 2025, primarily due to high research and development costs associated with their neuroprotective drug trials. The company saw a substantial decrease in total income and net assets over the period, while government grants contributed to the income. Cash reserves decreased significantly, reflecting the investment in ongoing drug development efforts. No dividends were declared, and the financial report was reviewed without significant audit issues.
Key Points
  • Argenica Therapeutics Limited reported a net loss of $3,816,831 for the half-year ended 31 December 2025.
  • Total income decreased significantly from $3,107,366 in the previous period to $720,169.
  • Research and development expenses were the largest expenditure, amounting to $3,032,222.
  • Net assets at 31 December 2025 were $3,443,280, a decrease from $7,237,271 on 30 June 2025.
  • The company received government grants totaling $626,739 during the half-year.
  • Cash and cash equivalents decreased to $5,037,373 from $10,555,160 at the start of the period.
  • The company is involved in the development of a neuroprotective therapeutic drug, specifically in Phase 2 trials for ischemic stroke patients.
  • There were no dividends declared for the half-year ended 31 December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.